Feed excerpt — reported by The Hill
The Food and Drug Administration's (FDA) committee on compounded drugs on Thursday broke with agency scientists and voted in favor of adding peptides to the list of substances compounding pharmacies can make, despite concerns being raised over the lack of demonstrated benefits. The FDA's Pharmacy Compounding Advisory Committee (PCAC) heard public comments and saw presentation by agency staffers concerning the peptides BPC-157, KPV, TB-500 and MOTS-C. These peptides are purported to help with ulcerative colitis, wound healing, obesity and osteoporosis.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at The Hill →